HIP invests in therapeutics, diagnostics, and devices with a focus on the oncology and cardiovascular sectors. HIP focuses primarily on IND through Phase 1 assets on the drug regulatory pathway and verification & validation and clinical stage assets in devices. HIP has a social focus on improving healthcare access and delivery.
HIP is focused primarily on investments in two indications, one of which is cardiovascular. Potential areas of investment include cardiac diagnostic tools or minimally invasive delivery techniques that often have shorter regulatory timelines than new drugs, as well as advanced therapies like gene and stem cell therapies aimed at conditions such as heart failure and arrhythmias.
HIP is focused primarily on investments in two indications, one of which is oncology. Potential areas of investment include therapeutics (antibody-drug conjugates (ADCs), cancer vaccines (mRNA tech), cell therapies, targeted therapies, radioligands) and diagnostics and monitoring (advanced imaging, liquid biopsies).
HIP is has a 20% allocation for opportunist investments outside of the cardiovascular and oncology indications.